News, views, and coverage of important topics and discussions from oncology conferences and events.
Necessity for Increased Screening for Genetic Testing Eligibility Among Long-Term Breast Cancer Survivors
Breast cancer survivors may test positive for pathogenic germline variants 10 years after their original diagnosis. Germline genetic testing may be an important tool for managing care.
Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes.
Telemedicine Program Provides High-Quality Anticancer Medication Delivery and Management for Veterans
The VA CARES program provides coordinated cancer care for veterans prescribed oral antineoplastic therapies who may lack access to comprehensive medication management resources.
Real-Life Study of Alpelisib plus Fulvestrant Therapy After Treatment with CDK4/6 Inhibitor in French Breast Cancer Patients
Alpelisib plus fulvestrant combination therapy improves progression-free survival while maintaining effectiveness in patients with HR-positive/HER2-negative advanced breast cancer in a French early access study.
Implications for Use of Subjective Social Status as a Risk Factor for Metabolic Syndrome in Black Women with New Breast Cancer Diagnosis
Metabolic syndrome is associated with poor prognosis in patients with breast cancer. Identifying potential risk factors for metabolic syndrome may improve outcomes in these women.
Inflammatory Responses to Neoadjuvant Chemotherapy Can Be Regulated by Moderate Physical Exercise Prior to Surgery
Moderate physical activity reduced the inflammatory response triggered by neoadjuvant chemotherapy in breast cancer patients prior to surgery. The benefit appears to be lost after surgery.
Assessment of Factors That Influence Psychosocial Function in Breast Cancer Patients After Treatment
Diverse factors contribute to shifts in psychosocial function in breast cancer patients after treatment. Understanding these factors provides opportunities for patients to receive more holistic care.
Identification of Biomarkers for HER2-Negative Advanced Breast Cancer Is Influenced by Race: A Real-World Study
Actionable biomarkers associated with directed treatment to prevent or reverse symptoms in African Americans with advanced-stage breast cancer may reduce mortality rates.
Treatment with Alpelisib plus Fulvestrant Achieves Long-Term Disease Control in Endocrine-Resistant (HR-Positive/HER2-Negative) Advanced Breast Cancer
The SOLAR-1 and X2101 trials demonstrate long-term disease control can be attained for ≥18 months with alpelisib plus fulvestrant in patients with hard-to-treat HR-positive/HER2-negative advanced breast cancer.
Behavioral Interventions Demonstrate Improved Long-Term Adherence to Adjuvant Endocrine Therapy Among Women with HR-Positive Breast Cancer
Many women with HR-positive breast cancer contend with emotional distress during prolonged adjuvant endocrine therapy. Behavioral interventions show promise as effective strategies to reduce stress and improve adherence to therapy.